Narcolepsy with cataplexy is a sleep disorder characterized by excessive daytime sleepiness, irresistible sleep episodes, and sudden loss of muscle tone (cataplexy) mostly triggered by emotions. Narcolepsy with cataplexy is a disabling lifelong disorder frequently arising during childhood. Pediatric narcolepsy often results in severe learning and social impairment. Improving awareness about this condition increases early diagnosis and may allow patients to rapidly access adequate treatments, including pharmacotherapy and/or non-medication-based approaches. Even though children currently undergo pharmacotherapy, data about safety and efficacy in the pediatric population are scarce. Lacking international guidelines as well as drugs registered for childhood narcolepsy with cataplexy, physicians have no other alternative but to prescribe in an off-label manner medications identical to those recommended for adults. We retrospectively evaluated 27 children ranging from 6 to 16 years old, suffering from narcolepsy with cataplexy, who had been treated with off-label sodium oxybate and had been followed in a clinical setting. Throughout a semi-structured interview, we documented the good efficacy and tolerability of sodium oxybate in the majority of the patients. This study constitutes a preliminary step towards a further randomized controlled trial in childhood narcolepsy with cataplexy.

Tolerance and efficacy of sodium oxybate in childhood narcolepsy with cataplexy: a retrospective study / Lecendreux, M.; Poli, F.; Oudiette, D.; Benazzouz, F.; Donjacour, C. E.; Franceschini, C.; Finotti, E.; Pizza, F.; Bruni, O.; Plazzi, G.. - In: SLEEP. - ISSN 0161-8105. - 35:5(2012), pp. 709-711. [10.5665/sleep.1836]

Tolerance and efficacy of sodium oxybate in childhood narcolepsy with cataplexy: a retrospective study

Poli F.;Plazzi G.
2012

Abstract

Narcolepsy with cataplexy is a sleep disorder characterized by excessive daytime sleepiness, irresistible sleep episodes, and sudden loss of muscle tone (cataplexy) mostly triggered by emotions. Narcolepsy with cataplexy is a disabling lifelong disorder frequently arising during childhood. Pediatric narcolepsy often results in severe learning and social impairment. Improving awareness about this condition increases early diagnosis and may allow patients to rapidly access adequate treatments, including pharmacotherapy and/or non-medication-based approaches. Even though children currently undergo pharmacotherapy, data about safety and efficacy in the pediatric population are scarce. Lacking international guidelines as well as drugs registered for childhood narcolepsy with cataplexy, physicians have no other alternative but to prescribe in an off-label manner medications identical to those recommended for adults. We retrospectively evaluated 27 children ranging from 6 to 16 years old, suffering from narcolepsy with cataplexy, who had been treated with off-label sodium oxybate and had been followed in a clinical setting. Throughout a semi-structured interview, we documented the good efficacy and tolerability of sodium oxybate in the majority of the patients. This study constitutes a preliminary step towards a further randomized controlled trial in childhood narcolepsy with cataplexy.
2012
35
5
709
711
Tolerance and efficacy of sodium oxybate in childhood narcolepsy with cataplexy: a retrospective study / Lecendreux, M.; Poli, F.; Oudiette, D.; Benazzouz, F.; Donjacour, C. E.; Franceschini, C.; Finotti, E.; Pizza, F.; Bruni, O.; Plazzi, G.. - In: SLEEP. - ISSN 0161-8105. - 35:5(2012), pp. 709-711. [10.5665/sleep.1836]
Lecendreux, M.; Poli, F.; Oudiette, D.; Benazzouz, F.; Donjacour, C. E.; Franceschini, C.; Finotti, E.; Pizza, F.; Bruni, O.; Plazzi, G.
File in questo prodotto:
File Dimensione Formato  
aasm.35.5.709.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 498.3 kB
Formato Adobe PDF
498.3 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1206037
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 43
social impact